According to the Sinus & Allergy Wellness Center, Sinusitis complicates 0.5% of upper respiratory tract infections and approximately 30 million adults are impacted by the condition in the United States itself. Since it causes billions of dollars in economic impact and several days of lost time from work, sinusitis therapeutics are receiving a broad focus on research from several companies. Currently, new monoclonal antibodies are being investigated as useful treatments for some inflammatory or infectious diseases affecting the nasal cavities. These innovative developments have impacted the pipeline analysis significantly.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing sinusitis pipeline development activities related to sinusitis are covered.
Common sinusitis drugs include decongestants, over-the-counter cold and allergy medications, nasal saline rinses and drinking plenty of fluids among others. Chronic sinusitis is treated by topical antihistamine sprays or oral pills, intranasal steroid sprays, leukotriene antagonists, like montelukast and surgeries among others. Other sinusitis therapeutic drugs given to treat the disease include augmentin, amoxicillin, levofloxacin, doxycycline, cefpodoxime, cefixime, and clindamycin among others.
Several pharma companies and institutes are developing innovative treatments to manage sinusitis. For instance, in January 2024, Optinose, a pharmaceutical company announced the publication of a reopened phase III clinical trial program which evaluated xhance for the treatment of adults with chronic sinusitis. This unique product combines nasal anti-inflammatory drugs with the exhalation delivery system. Several innovative sinusitis drug candidates are currently in the pipeline which is being developed by major pharma companies and institutions, impacting the sinusitis pipeline analysis.
This product will be delivered within 3-5 business days.
Report Coverage
The Sinusitis Pipeline Report by the publisher gives comprehensive insights into sinusitis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for sinusitis. The sinusitis pipeline insight includes the analysis of over 100 pipeline drugs and 50+ companies . It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from sinusitis.The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing sinusitis pipeline development activities related to sinusitis are covered.
Sinusitis Pipeline Outlook
Sinusitis is the swelling or inflammation of the tissue lining the sinuses. Sinuses are parts inside the face which are normally filled with air. The infections like bacterial infections, viral infections and allergies can irritate them, and cause them to get blocked and filled with fluid. This creates pressure, pain in the face, and nasal congestion among other symptoms. There are multiple types of sinusitis such as acute, subacute, chronic, and recurrent sinusitis, bacterial and viral sinusitis, and fungal sinusitis. The common symptoms of the disease are postnasal drip, stuffy nose, runny nose with thick green or yellow mucus, facial pressure, pressure or pain in the ear, teeth, fever, cough, headache, and tiredness, among others.Common sinusitis drugs include decongestants, over-the-counter cold and allergy medications, nasal saline rinses and drinking plenty of fluids among others. Chronic sinusitis is treated by topical antihistamine sprays or oral pills, intranasal steroid sprays, leukotriene antagonists, like montelukast and surgeries among others. Other sinusitis therapeutic drugs given to treat the disease include augmentin, amoxicillin, levofloxacin, doxycycline, cefpodoxime, cefixime, and clindamycin among others.
Several pharma companies and institutes are developing innovative treatments to manage sinusitis. For instance, in January 2024, Optinose, a pharmaceutical company announced the publication of a reopened phase III clinical trial program which evaluated xhance for the treatment of adults with chronic sinusitis. This unique product combines nasal anti-inflammatory drugs with the exhalation delivery system. Several innovative sinusitis drug candidates are currently in the pipeline which is being developed by major pharma companies and institutions, impacting the sinusitis pipeline analysis.
Sinusitis - Drug Pipeline Therapeutic Assessment
This section of the sinusitis report covers the analysis of sinusitis drugs based on several segmentations including:By Phase
The pipeline assessment report covers 50+ drug analyses based on phase.- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The sinusitis therapeutic assessment report covers 50+ drug analyses based on molecule classes:
- Antibody
- Antisense Oligonucleotides
- Immunotherapy
- Monoclonal Antibody
- Peptides
- Protein
- Recombinant Protein
- Small Molecule
- Stem Cell
- Vaccine
By Route of Administration
The sinusitis clinical assessment report covers 50+ drug analyses based on the route of administration.- Oral
- Parenteral
- Others
Sinusitis - Pipeline Assessment Segmentation, By Phases
The sinusitis report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total clinical trials for sinusitis.Sinusitis - Pipeline Assessment Segmentation, By Drug Molecules
The drug molecules categories covered under sinusitis pipeline analysis include antibody, antisense oligonucleotides, immunotherapy, monoclonal antibody, peptides, protein, recombinant protein, small molecule, stem cell and vaccine. Several monoclonal antibodies have shown a positive impact on the treatment process for sinusitis. Dupilumab is another monoclonal antibody which has been proven effective in managing allergies. It reduces inflammation and helps in preventing the formation of nasal polyps. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for sinusitis.Sinusitis Clinical Trials Assessment - Competitive Dynamics
The sinusitis report insights for the sinusitis drug pipeline cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in sinusitis clinical trials:- Tivic Health Systems
- SinuSafe Medical LTD
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Galsor S.r.l.
- Bayer AG
- Pfizer & Co., Inc.
- Sanofi SA
- Entellus Medical, Inc.
- Naryx Pharma Inc.
- Probionase Therapies Inc.
- SinuSys Corporation
- Integra LifeSciences Corporation
- Others
Sinusitis - Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for sinusitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of sinusitis drug candidates.Drug: levofloxacin
The trial is designed to evaluate the safety and effectiveness of two antibiotic regimens in acute bacterial sinusitis treatment. The trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and is currently under phase III.Biological: Saline solution
The objective of the study is to assess the effects of SINUclean DM spray. This spray is added to the standard therapy for sinusitis. The study is being conducting to check the safety of spray and whether it is capable to determine the resolution of the symptoms in a shorter time.Drug: Moxifloxacin
Bayer is developing the sinusitis drug candidate and it is currently under phase III. The study is being conducted to assess the safety and effectiveness of Avelox in a 5-day treatment of adult patients having acute bacterial sinusitis.Reasons To Buy This Report
The Sinusitis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for sinusitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into sinusitis collaborations, market trends, regulatory environments, and potential growth opportunities within sinusitis pipeline insights.Key Questions Answered in the Sinusitis - Pipeline Assessment Report
- What is the current landscape of Sinusitis pipeline drugs?
- Which companies/institutions are developing Sinusitis emerging drugs?
- How many phase II drugs are currently present in Sinusitis pipeline drugs?
- Which company is leading the Sinusitis pipeline development activities?
- What is the current Sinusitis therapeutic assessment?
- What are the opportunities and challenges present in the Sinusitis drug pipeline landscape?
- What is the efficacy and safety profile of Sinusitis pipeline drugs?
- Which companies/institutions are involved in Sinusitis collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in Sinusitis?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Sinusitis
4 Patient Profile
5 Sinusitis: Epidemiology Snapshot
6 Sinusitis: Market Dynamics
7 Sinusitis: Key Facts Covered
8 Sinusitis, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Sinusitis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Sinusitis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Sinusitis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Sinusitis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Sinusitis, Key Drug Pipeline Companies
